28/10/2026
🙏🏼🙏🏼🙏🏼
Japanese researchers have developed FeliAIM, an experimental treatment targeting chronic kidney disease in cats — one of the leading causes of illness and death in older felines. Led by Toru Miyazaki, the research team submitted the drug for regulatory approval in Japan on April 24, 2026.
Early studies showed meaningful improvements in survival rates among cats with advanced kidney disease. While headlines have circulated about the potential to extend average feline lifespans, the reality is more measured: the treatment shows genuine promise, but claims of routinely doubling lifespan to 30 years remain unproven and require further evidence.
If approved, FeliAIM could offer a new option for veterinarians treating one of the most common chronic conditions we see in senior cats. For countless cat lovers watching their aging companions struggle with kidney disease, this development represents hope — and a reminder of how veterinary science continues to evolve in service of feline health.
